Jeffrey Zonder, MD

Articles

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

February 20th 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Dr Zonder on Unmet Needs to be Addressed in Multiple Myeloma

February 13th 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

Clinical Pearls and Future Directions in AL Amyloidosis

January 22nd 2024

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

January 22nd 2024

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Adverse Event Management in AL Amyloidosis

January 15th 2024

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

January 15th 2024

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Birtamimab Safety Profile in the VITAL Study

January 8th 2024

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

January 8th 2024

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Limitations of Available Treatment Options for Patients with Cardiac Involvement

January 8th 2024

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Treatment Approaches in AL Amyloidosis

January 8th 2024

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Navigating the Differential Diagnosis of AL Amyloidosis

December 20th 2023

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

AL Amyloidosis: Background, Patient Profile, and Staging

December 20th 2023

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

Dr Zonder on Ongoing Research at Karmanos Cancer Institute in Multiple Myeloma

June 1st 2023

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

Dr Zonder on the Real-World Use of Ixazomib-based Therapy in R/R Multiple Myeloma

May 26th 2023

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Dr Zonder on the Management of Bispecific Antibody–Associated Toxicities in Multiple Myeloma

May 12th 2023

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Dr Zonder on the Promise of Talquetamab and Cevostamab in R/R Multiple Myeloma

April 7th 2023

Jeffery Zonder, MD, discusses the derived benefit that has been derived from talquetamab and cevostamab in patients with relapsed/refractory multiple myeloma.

Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma

March 24th 2023

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

Dr Zonder on CAR T-cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Myeloma

March 23rd 2023

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Zonder on the ZUMA-2 and ZUMA-5 Trials in MCL and iNHL

September 22nd 2020

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.